Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA – Get Free Report)’s share price shot up 0.7% during trading on Monday . The company traded as high as $1.61 and last traded at $1.42. 376,116 shares traded hands during mid-day trading, an increase of 262% from the average session volume of 103,829 shares. The stock had previously closed at $1.41.
Analyst Ratings Changes
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Genenta Science in a research report on Monday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.
Read Our Latest Analysis on GNTA
Genenta Science Stock Performance
Genenta Science (NASDAQ:GNTA – Get Free Report) last issued its quarterly earnings data on Friday, October 10th. The company reported ($0.10) earnings per share for the quarter. Sell-side analysts predict that Genenta Science S.p.A. Unsponsored ADR will post -0.93 EPS for the current fiscal year.
Hedge Funds Weigh In On Genenta Science
A hedge fund recently bought a new stake in Genenta Science stock. Citadel Advisors LLC bought a new position in shares of Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA – Free Report) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm bought 12,486 shares of the company’s stock, valued at approximately $41,000. Citadel Advisors LLC owned about 0.07% of Genenta Science as of its most recent SEC filing. Hedge funds and other institutional investors own 15.13% of the company’s stock.
About Genenta Science
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
Featured Articles
- Five stocks we like better than Genenta Science
- Trading Stocks: RSI and Why it’s Useful
- Post 35% Surge, Analysts Eye More Upside in Copper Giant Freeport
- How to Invest in Blue Chip Stocks
- Why a SpaceX IPO Could Be a Major Catalyst for GOOGL Stock
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Can Upwork Maintain Its Comeback? Reasons to Be Bullish and Bearish
Receive News & Ratings for Genenta Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genenta Science and related companies with MarketBeat.com's FREE daily email newsletter.
